Emodin and rhein composition and application thereof
Through the use of emodin and rhubarbic acid compositions, it effectively inhibits intracellular bacteria infections such as Mycobacterium tuberculosis, non-tuberculosis, Brucella and Mycoplasma avians in livestock and poultry, and solves the poor effect of existing antibacterial drugs. The problem has achieved the effect of reducing the incidence of livestock and poultry and improving production performance.
Patent Information
- Application Number
- CN202411051053.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antibacterial drugs are difficult to effectively inhibit intracellular bacteria infections such as Mycobacterium tuberculosis, non-tuberculosis, Brucella and Mycoplasma avian in livestock and poultry, resulting in high incidence and death rates of livestock and poultry, and the treatment cost Higher.
Provide a composition of emodin and rhubarb acid, with a mass ratio of (10-50): (5-10), and is combined with pharmaceutical excipients or excipients, and is prepared into antibacterial agents or antibacterial agents for the preparation of granules, Powders, oral liquids, perfusion agents, tablets or injections are used to prevent and treat intracellular bacterial infections in livestock and poultry.
This composition can effectively inhibit intracellular bacteria infections such as Mycobacterium tuberculosis, non-tuberculosis, Brucella and Mycoplasma aviano, reduce the incidence and death rate of livestock and poultry, improve survival rate and production performance, and Low cost and easy preparation process.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of agricultural biotechnology, and in particular relates to a rhein and rhein composition and application thereof. Background Art
[0002] Anthraquinone compounds are widely distributed in medicinal plants, mostly in natural plants such as Rubiaceae, Polygonaceae, Leguminosae, Rhamnaceae, and Liliaceae. They are the main active ingredients of many traditional Chinese medicines (such as rhubarb, Polygonum multiflorum, Cassia seed, Polygonum cuspidatum, Senna leaf, Aloe, etc.), and various anthraquinone components have a wide range of pharmacological activities, such as antibacterial and anti-inflammatory, antiviral, antioxidant, anti-mutagenic, anti-cancer, anti-ultraviolet, liver and gallbladder protection, eyesight, hemostasis and blood circulation, sleep promotion, lipid-lowering, and immune function enhancement. Free physcion methyl ether from rhubarb has growth inhibition effects on bacteria such as Escherichia coli, Staphylococcus aureus, Bacillus subtilis, Lactobacillus and Bifidobacterium. Among them, the best antibacterial effect is on Escherichia coli, and the inhibition rate can reach 75.78% at a concentration of 256 μg / mL. Physcion methyl ether can also inhibit the growth and reproduction of Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, and Acinetobacterium mentagrophytes. Physcion has the activity of inhibiting the growth of Helicobacter pylori, and it shows a dose-effect relationship. Physcion also has a strong antibacterial effect on common pathogens in aquaculture, such as Aeromonas sobria, Aeromonas hydrophila, and Proteus. Huo Liyun found in the experiment that anthraquinone compounds in the active ingredients of aloe vera are the main antibacterial substances with a certain broad spectrum, and have a certain inhibitory effect on Escherichia coli, Proteus, Staphylococcus aureus, Pseudomonas aeruginosa, and Shigella flexneri. At the same time, Sompong Boonsr et al. conducted a specific evaluation of the antibacterial properties of three known anthraquinone compounds in the roots of the genus Achyranthes. The experiment showed that the known anthraquinone compounds have a good antibacterial effect on Bacillus subtilis, Staphylococcus aureus, Streptococcus, and Salmonella typhi. In addition, rhubarb anthraquinone compounds have an inhibitory effect on respiratory syncytial virus and have a strong anti-influenza virus effect in vitro. With the increase of concentration, its antiviral activity increases, and the virus inhibition rate increases. When the concentration reaches 160 μg / mL, it can reduce more than 50% of the host cell lesions. In short, this type of substance is a natural product with great development value, and its application in the field of livestock and poultry diseases has very broad prospects. Summary of the invention
[0003] The purpose of the present invention is to provide a rhein and rhein composition and application thereof.
[0004] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides a composition of rhein and rhein, wherein the mass ratio of the active ingredients rhein and rhein is (10-50):(5-10), preferably 5:1.
[0005] Furthermore, the composition also includes pharmaceutical adjuvants or excipients.
[0006] Furthermore, the mass percentages of emodin and rhein in the composition are 10-50% and 5-10% respectively, and the rest are pharmaceutical adjuvants or excipients.
[0007] Preferably, the composition contains 50% emodin, 10% rhein and 40% pharmaceutical adjuvants or excipients; wherein % is percentage by mass.
[0008] The pharmaceutical excipient of the present invention can be selected from at least one of medium chain triglycerides, 1,2-propylene glycol, Tween-20, Tween-80 and the like.
[0009] The excipient of the present invention can be selected from at least one of starch, dextrin, lactose, stevioside, sucrose, glycyrrhizin, fructose syrup, sucralose, xylitol, sorbitol, glucose, pregelatinized starch, sodium carboxymethyl starch and the like.
[0010] In a second aspect, the present invention provides use of the composition in the preparation of an antibacterial agent or an antibacterial drug.
[0011] The bacteria are selected from Mycobacterium tuberculosis, non-tuberculous mycobacteria, Brucella (bovine, ovine and porcine types), and avian mycoplasma.
[0012] In a third aspect, the present invention provides use of the composition in the preparation of a medicament for preventing and treating intracellular bacterial infection in livestock and poultry.
[0013] The intracellular bacterial infection of livestock and poultry is caused by Mycobacterium tuberculosis, non-tuberculous mycobacteria, Brucella (bovine, ovine and porcine types) or avian mycoplasma.
[0014] Wherein, the avian mycoplasma includes but is not limited to Mycoplasma gallisepticum and Mycoplasma synoviae.
[0015] Furthermore, the medicine can be in the form of granules, powders, oral solutions, infusions, tablets or injections.
[0016] The effective dosage of the rhein and rhein composition of the present invention for preventing and treating intracellular bacteria in livestock and poultry is 5-10 mg / kg body weight, and it is used continuously for 5-7 days.
[0017] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects: The Chinese medicinal composition of rhein and rhein provided by the present invention has easy-to-obtain raw materials, low cost and simple preparation process. The composition can effectively inhibit diseases caused by intracellular bacteria infection such as tuberculosis mycobacterium, non-tuberculous mycobacteria, brucella and poultry mycoplasma in livestock and poultry, thereby greatly reducing the morbidity and mortality rate of livestock and poultry, and effectively improving the survival rate and production performance of livestock and poultry. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is the emodin precipitate prepared in Example 1 of the present invention.
[0019] Figure 2 This is the rhein precipitate prepared in Example 2 of the present invention.
[0020] Figure 3 The rhein powder prepared in Example 2 of the present invention.
[0021] Figure 4 The results of in vitro inhibition of Mycoplasma gallisepticum HS strain in Experimental Example 1 of the present invention are shown in Figure 1. Wherein, + represents bacterial growth, and - represents bacterial inhibition.
[0022] Figure 5 This is the comparison of the effects of rhein and rhein in treating tuberculous mastitis in Experimental Example 4 of the present invention. Among them, 1 is the rifampicin injection group; 2-3 are high-dose rhein and rhein; 4-5 are medium-dose rhein and rhein; and 6 is the blank control group.
[0023] Figure 6 This is the in vitro inhibition test of tuberculosis bacillus by rhein and rhein in Experimental Example 6 of the present invention, wherein 1 is the rhein and rhein group, and 2 is the rhein and rhein control group. DETAILED DESCRIPTION
[0024] The present invention aims to provide a new use of the combination of emodin and rhein and its antagonistic effect on intracellular bacterial infection, namely, a method for preparing emodin and rhein oral liquid, perfusion liquid, injection, granule, tablet, powder and other dosage forms. The intracellular bacterial infection of livestock and poultry includes infection with bacteria such as Mycobacterium tuberculosis, nontuberculous mycobacteria, Brucella and avian mycoplasma.
[0025] In vitro inhibition tests showed that the Chinese herbal composition of rhein and rhein had moderate inhibitory activity against bovine tuberculosis Mycobacterium, non-tuberculous mycobacteria, and Brucella (bovine, ovine and porcine types), and highly sensitive inhibition against Mycoplasma gallisepticum and Mycoplasma synoviae.
[0026] By injecting the traditional Chinese medicine composition of rhein and rhein, the tuberculosis mycobacterium, non-tuberculosis mycobacteria and Brucella in the blood of livestock can be effectively killed, the milk production and weight of dairy cows can be increased, and the respiratory morbidity of cattle can be reduced. After taking rhein and rhein orally, the respiratory morbidity and mortality caused by intracellular bacteria in poultry can be reduced.
[0027] The present invention adopts the following technical solution: The invention provides a rhein-rhein Chinese medicine composition, which is a mixture of rhein and rhein alcohol extracts and acid-base extractions in a certain proportion, and also includes conventional pharmaceutical adjuvants and excipients.
[0028] Specifically, the present invention provides a Chinese medicinal composition of rhein and rhein, which is prepared from the following raw materials in parts by weight: 10-50 parts of rhein and 5-10 parts of rhein.
[0029] Preferably, the Chinese medicine composition is made of the following raw materials in weight: 50% of rhein and 10% of rhein. More preferably, in the Chinese medicine composition, the weight ratio of rhein, rhein and auxiliary materials is 5:1:4.
[0030] The traditional Chinese medicine composition also includes conventional excipients such as medium chain triglycerides, 1,2-propylene glycol, Tween-20 or Tween-80.
[0031] The Chinese medicine composition also includes conventional pharmaceutical excipients such as starch, dextrin, lactose, stevioside, sucrose, glycyrrhizin, fructose syrup, sucralose, xylitol, sorbitol, glucose, pregelatinized starch and / or sodium carboxymethyl starch.
[0032] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0033] Example 1 Preparation of Rhein Extract
[0034] The ratio of the raw material of Polygonum cuspidatum to 75% ethanol is 1:15 (g:mL), the extraction time is 5h, the extraction temperature is controlled at 60℃, and after concentration (the concentration ratio is 1:5, that is, concentrated to 1 / 5 of the original volume), 3 volumes of ether are added. Then, 5% sodium carbonate solution is added, the pH is adjusted to 9.0-11.0, and the extraction is carried out for 2 hours. The lower aqueous solution is collected and stirred for 30 minutes. The reaction temperature is 35℃, and 5M HCl is used for acidification to adjust the pH to 5.0. After the acidification is completed, the precipitate is collected and dried at 50℃ to obtain rheumatoid artemisia powder. The yield of rheumatoid artemisia is 89.1%, and the content of rheumatoid artemisia is above 92.5%.
[0035] The emodin precipitate prepared in Example 1 is shown in Figure 1 .
[0036] Example 2 Preparation of rhein extract
[0037] The ratio of the raw material of Polygonum cuspidatum to 75% ethanol is 1:15 (g:mL), the reflux extraction time is 5h, the filtrate is concentrated 25 times under reduced pressure, and then 3 volumes of ether are added. Then, 5% sodium carbonate solution is added, the pH is adjusted to 9.0-11.0, extraction is carried out for 2 hours, the lower aqueous solution is collected, and the reaction is stirred for 30 minutes. The reaction temperature is 35°C, 5M HCl is used for acidification to adjust the pH to 2.0, suction filtration, concentration to obtain an orange-red precipitate, 90% ethanol is added for recrystallization, and drying is carried out. The yield of rhein is 9.8%, and the content of the prepared rhein is more than 90%.
[0038] The rhein precipitate prepared in Example 2 is shown in Figure 2 , Rhein powder Figure 3 .
[0039] The comparison between the improved ethanol reflux-acid-base solution extraction method and the traditional extraction method in Examples 1 and 2 is shown in Table 1.
[0040] Table 1 Comparison between the improved ethanol reflux-acid-base solution extraction method and the traditional extraction method
[0041] The traditional extraction method is as follows: The orthogonal test method was used to optimize the extraction process of rhein from Polygonum cuspidatum. Taking the content of rhein as the evaluation index, it was found that the order of influencing factors was solvent dosage > solvent concentration > extraction time. The best extraction process was 10 times the volume concentration of 70% ethanol, extraction time of 2 h, and the extraction rate of rhein was 1.2%. See reference: Wang Jian, Li Xiangyang, Li Zhenguo. Optimization of the extraction process of Polygonum cuspidatum by orthogonal test method. Journal of Traditional Chinese Medicine, 2010, 23(8): 17-19.
[0042] Traditionally, dynamic tank group countercurrent extraction is used: the best extraction process is to use 10 times the volume of 70% ethanol at 65 ℃ for a single extraction for 65 minutes, and the extraction rate of rhein is 0.8%. See references: Qi Yi; Cai Ming; Xie Zhipeng; Qu Haibin; Cheng Yiyu, Comparison of dynamic tank group countercurrent extraction processes for rhein from Polygonum cuspidatum. Journal of Chinese Herbal Medicine, 2008.8:117-1174.
[0043] The rhein and rhein used in the following examples are the rhein extract and rhein extract prepared in Examples 1 and 2.
[0044] Example 3 Preparation of compound rhein and rhein soluble powder
[0045] Optimized ratio 1: The drug is prepared into a soluble powder by mixing emodin, rhein and maltodextrin in a weight ratio of 5:1:4.
[0046] Screening ratio 2: The drug is prepared into a soluble powder by mixing emodin, rhein and maltodextrin in a weight ratio of 4:2:4.
[0047] Screening ratio 3: The drug is prepared into a soluble powder by mixing emodin, rhein and maltodextrin in a weight ratio of 3:3:4.
[0048] Screening ratio 4: The drug is prepared into a soluble powder by mixing emodin, rhein and maltodextrin in a weight ratio of 2:4:4.
[0049] Screening ratio 5: The drug is prepared into a soluble powder by mixing emodin, rhein and maltodextrin in a weight ratio of 1:5:4.
[0050] Example 4 Preparation of Compound Rhein and Rhein Injection
[0051] Rhein 9 g, rhein 1 g, medium chain triglycerides 22.5 mL, 1,2-propylene glycol 25 mL, Tween-20 reagent 0.1 mL, water for injection add to 100 mL.
[0052] The solution is prepared by mixing emodin and rhein in a ratio of 9:1, and the liquid contains a drug concentration of 100 mg / mL. The compound is a brown-yellow liquid, and the extract is easily dispersed when stored for a long time. The pH is 3~4, and the relative density is 1.05~1.08 (it should not be less than 1.01).
[0053] Example 5 Preparation of compound rhein and rhein oral solution
[0054] Rhein 7 g, rhein 3 g, medium chain triglycerides 22.5 mL, 1,2-propylene glycol 25 mL, Tween-20 reagent 0.1 mL, water for injection add to 100 mL.
[0055] The solution is prepared by mixing emodin and rhein in a ratio of 7:3, and the liquid contains a drug concentration of 100 mg / mL. The compound is a brown-yellow liquid, and the extract is easily dispersed when stored for a long time. The pH is 3~4, and the relative density is 1.05~1.08 (it should not be less than 1.01).
[0056] Example 6 Preparation of compound rhein and rhein oral solution
[0057] Rhein 6 g, rhein 4 g, medium chain triglycerides 22.5 mL, 1,2-propylene glycol 25 mL, Tween-20 reagent 0.1 mL, and water for injection to 100 mL.
[0058] The solution is prepared by mixing emodin and rhein in a ratio of 6:4, and the liquid contains a drug concentration of 100 mg / mL. The compound is a brown-yellow liquid, and the extract is easily dispersed when stored for a long time. The pH is 3~4, and the relative density is 1.05~1.08 (it should not be less than 1.01).
[0059] Example 7 Preparation of compound rhein and rhein oral solution
[0060] Rhein 1 g, rhein 1 g, medium chain triglycerides 22.5 mL, 1,2-propylene glycol 25 mL, Tween-20 reagent 0.1 mL, and water for injection to 100 mL.
[0061] The solution is prepared by mixing emodin and rhein in a ratio of 1:1, and the liquid contains a drug concentration of 100 mg / mL. The compound is a brown-yellow liquid, and the extract is easily dispersed when gently shaken after long-term storage, with a pH of 3~4 and a relative density of 1.05~1.08 (required to be no less than 1.01).
[0062] Example 8 Preparation of Compound Rhein and Rhein Oral Liquid
[0063] Rhein 3 g, rhein 7 g, medium chain triglycerides 22.5 mL, 1,2-propylene glycol 25 mL, Tween-20 reagent 0.1 mL, water for injection add to 100 mL.
[0064] The solution is prepared by mixing emodin and rhein in a ratio of 3:7, and the liquid contains a drug concentration of 100 mg / mL. The compound is a brown-yellow liquid, and the extract is easily dispersed when stored for a long time. The pH is 3~4, and the relative density is 1.05~1.08 (it should not be less than 1.01).
[0065] Example 9 Preparation of Compound Rhein and Rhein Granules
[0066] The drug is prepared by mixing 50 g of rhein and rhein extract, 150 g of dextrin and 50 g of sucrose in a weight ratio of 9:1, making granules, drying, whole granules, passing through a 16-mesh sieve and shaking to obtain the drug.
[0067] Experimental Example 1 In vitro inhibition test of rhein-rhein preparation on poultry mycoplasma
[0068] 1 Materials and methods
[0069] 1.1 Test strains
[0070] There are six strains of avian mycoplasma, including MG-F, MG-HS, MG-S6, FZ, MS-FJ01 and MS-QD.
[0071] MG-F, MG-HS, and MG-S6 are Mycoplasma gallisepticum, which are preserved by the College of Veterinary Medicine of Huazhong Agricultural University.
[0072] The FZ and MS-FJ01 isolates of MS were Mycoplasma synoviae, which were preserved by the Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences; the MS-QD vaccine strain was purchased from the China Veterinary Drug Administration.
[0073] 1.2 Experimental drugs and reagents
[0074] 1.2.1 Trial Drugs
[0075] 5% and 2% rhein and rhein solutions (initial drug concentrations were 50 and 20 mg / mL, respectively)
[0076] 1.2.2 Main reagents
[0077] 1.2.2.1 Culture reagents
[0078] Yeast extract, thallium acetate, agar powder, penicillin, pig serum
[0079] 1.2.2.2 General chemical reagents
[0080] Sodium hydroxide, sodium chloride, potassium chloride, magnesium sulfate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and phenol red were all domestic analytical grade reagents.
[0081] 1.2.3 Preparation of FM-4 medium
[0082] 1.2.3.1 FM-4 base fluid
[0083] Sterilize with high pressure steam at 115°C for 20 min and store at 4°C for later use.
[0084] 1.2.3.2 Improved FM-4 liquid medium
[0085] Adjust pH to 7.6-7.8 and store at 4°C for later use.
[0086] 1.2.3.3 Preparation of yeast extract
[0087] Dissolve 500g of fresh yeast in 2L of triple-distilled water; adjust the pH to about 4.5 with 1 mol / L hydrochloric acid; heat, stir, and maintain at 100℃ for about 30 min; cool rapidly, and centrifuge at 4000 r / min for 30 min; adjust the pH to about 8.0 with 1 mol / L sodium hydroxide; divide into portions, and sterilize with high-pressure steam at 115℃ for 20 min; store at -20℃ for later use.
[0088] 1.2.4 1% phenol red solution
[0089] Weigh 0.2 g of phenol red, grind it, add 600 μL of 1 mol / L sodium hydroxide, dissolve it, add distilled water to 20 mL, filter and sterilize it, and store it in a dark place.
[0090] 1.3 Test methods
[0091] 1.3.1 Recovery and culture of avian mycoplasma
[0092] Six strains of avian mycoplasma, including MG-F, MG-HS, MG-S6, FZ, MS-FJ01 and MS-QD, were inoculated into 2 mL of liquid culture medium and then cultured in a 37 ℃ incubator for 3-5 days until the color changed (pink to orange), which was taken as the first subculture. The same method was used to subculture the third generation, and the color change unit (CCU) was determined. The culture was stored in a -20 ℃ refrigerator.
[0093] 1.3.2 Dilution of test drug
[0094] The drugs were diluted with sterile PBS to an initial concentration of 0.5%, and then doubled for subsequent antibacterial tests.
[0095] 1.3.3 Determination of color change units
[0096] Divide the culture medium into 10 sterile test tubes, 1.8 mL per tube. Add 0.2 mL of the test bacteria solution to the first tube, mix well, and pipette 0.2 mL into the second tube. Repeat this process to make 10-fold incremental dilutions. -1 -10 -9 (Note that you need to change the tip of the pipette each time). The tenth tube is used as the culture medium control. Then it is placed in a 37 ℃ incubator for 14 days, and its color change is observed every day. The result is determined when the color of the culture medium does not continue to change after 2 weeks of continuous culture. The highest dilution of the culture medium that changes color (pink to orange) is the CCU of the bacterial solution, that is, when the tested bacterial solution is diluted to this highest dilution, mycoplasma still grows.
[0097] 1.3.4 Determination of minimum inhibitory concentration (MIC) (test tube double dilution method)
[0098] The amount of inoculated bacterial solution (10 6 CCU / mL).
[0099] Take 12 sterilized test tubes, except for the first tube, add 0.9 mL of culture solution, and add 0.5 mL to the remaining tubes. Take 0.1 mL of drug stock solution and add it to the first tube. After mixing, pipette 0.5 mL into the second tube. Dilute to the last tube, and finally pipette 0.5 mL for sterility inspection. Then add 0.5 mL of diluted strain culture solution to each tube. At the same time, set up a bacterial solution control tube, a culture medium control tube, and a drug control tube (drugs are diluted with culture medium without adding strain culture solution). Put the test tubes with rubber stoppers in a 37 ℃ incubator for incubation. When the color of the culture medium in the control tube changes from pink to orange, determine the result (the drug dilution concentration of the tube before the color change is the minimum inhibitory concentration), and set up 2 replicates.
[0100] 2 Test results
[0101] Rhein and rhein were diluted in multiples with culture medium in a test tube, and then inoculated with bacterial suspensions of six test concentrations, including MG-F, MG-HS, MG-S6, FZ, MS-FJ01 and MS-QD, respectively, and cultured in an incubator at 37°C to observe the growth of avian mycoplasma in the test tube.
[0102] As shown in Table 2, for MG, the inhibition pore number of emodin is 8-9, and the inhibition pore number of rhein is 8; for MS, the inhibition pore number of emodin is 8-10, and the inhibition pore number of rhein is 8-10. The concentration of the original drug has a certain influence on the test, which may be due to the dilution of the reagent and the purity of the reagent.
[0103] After converting the drug content, the inhibitory concentration MIC of the tested drugs against avian mycoplasma is as follows: 0.9-1.95μg / mL for rhein and 0.9-1.95μg / mL for rhein.
[0104] Table 2 Inhibitory effects of rhein and rhein on avian mycoplasma
[0105] The comprehensive analysis of the results showed that when the concentration of rhein and rhein reached 1.95 μg / mL, the growth of avian mycoplasma could be effectively inhibited. There is no unified standard for the MIC of Chinese medicine against avian mycoplasma in China. The standard of similar experiments was used as the judgment standard, that is, when the MIC is ≤7.81 g / L of crude drug concentration, it is highly sensitive; when the MIC is between 7.81 and 250.00 g / L of crude drug concentration, it is moderately sensitive; when the MIC is greater than 250.00 g / L of crude drug concentration, it is insensitive. Six strains of avian mycoplasma, including MG-F, MG-HS, MG-S6, FZ, MS-FJ01 and MS-QD, showed high sensitivity to rhein and rhein.
[0106] Conclusion: Rhein and rhein have a significant effect on 10 6 The results showed that the minimum inhibitory concentration of emodin and rhein against 6 strains of avian mycoplasma, including MG-F, MG-HS, MG-S6, FZ, MS-FJ01 and MS-QD, was 1.95 μg / mL, indicating that avian mycoplasma was highly sensitive to emodin and rhein, and that emodin and rhein could effectively inhibit avian mycoplasma.
[0107] The results of experimental example 1 in vitro inhibition of Mycoplasma gallisepticum HS strain are shown in Figure 4 .
[0108] Experimental Example 2 Screening of formulas for the prevention and treatment of Mycoplasma gallisepticum by using rhein-rhein preparations
[0109] 1 Materials and methods
[0110] 1.1 Experimental animals: Ten-day-old broiler chickens were randomly divided into 8 groups, 10 in each group, for a total of 80 chickens.
[0111] 1.2 Drug grouping: rhein: rhein: excipient 5:1:4 group, rhein: rhein: excipient 4:2:4 group, rhein: rhein: excipient 3:3:4 group, rhein: rhein: excipient 2:4:4 group, rhein: rhein: excipient 1:5:4 (Example 3), tylosin tartrate group (Hebei New Century Animal Pharmaceutical Co., Ltd., batch number 20230807), infection control group, and healthy control group.
[0112] 1.3 Strains and reagents: The virulent HS strain of Mycoplasma gallisepticum was kindly donated by Professor Bi Dingren of the College of Veterinary Medicine of Huazhong Agricultural University. The culture medium for Mycoplasma gallisepticum was prepared according to the method described in the literature (Chinese Veterinary Pharmacopoeia Committee. Veterinary Pharmacopoeia of the People's Republic of China. Beijing: Chemical Industry Press. 2000.334).
[0113] Mycoplasma gallisepticum serum plate agglutination antigen, Mycoplasma gallisepticum positive serum: produced by China Veterinary Drug Administration.
[0114] 1.4 Artificial disease model and administration method: Artificial infection with 0.3 ml / 100 g of virulent HS strain culture of Mycoplasma gallisepticum (third generation subculture of Mycoplasma gallisepticum, growth turbidity of 1×10 8 CFU) of chickens were administered medication 21 days after infection (Table 3).
[0115] 1.5 Evaluation indicators: Record the death situation every day, dissect the dead chickens, and observe the air sac lesions. The infected chickens are judged as positive if they grunt, open their mouths, pant, and have mucus in their nasal cavity. After 20 days of infection, weigh the surviving chickens in each group, collect blood and separate serum for serum plate agglutination reaction, detect the antibodies of Mycoplasma gallisepticum in broilers, and dissect all the chickens to observe the air sac lesions. The air sacs on each side are divided into 5 grades. The more severe the lesions, the higher the score (Ning Yibao. Antibacterial test of Mycoplasma gallisepticum in vitro and treatment test of Mycoplasma gallisepticum by Mycoplasma gallisepticum. Chinese Journal of Veterinary Medicine, 2000, 34(6):56-58).
[0116] Level 0: The air sac is normal, thin and transparent, and 0 points are given.
[0117] Grade 1: The air sac has only slightly thickened gray areas or yellow exudative spots, which is scored as 2 points.
[0118] Grade 2: Gray to yellow exudate is easily seen in some air cells, sometimes foam appears, and the air cells are thickened, and 4 points are recorded.
[0119] Grade 3: Most of the air sacs are thickened and covered with a large amount of yellow-white cheesy exudate, with a score of 6.
[0120] Grade 4: Almost the entire air sac is covered with yellow-white cheesy exudate and the air sac is severely thickened, with a score of 8.
[0121] Average pathological injury score of chicken air sac = total injury degree of all chicken air sacs / number of inspected chickens
[0122] The percentage of airbag injury reduction was calculated based on the airbag injury scoring results.
[0123] The percentage of reduction of air sac lesions = (the average score of air sac lesions per chicken in the infection control group - the average score of air sac lesions per chicken in the experimental group) / the average score of air sac lesions per chicken in the infection control group.
[0124] Table 3 Drug groups and administration methods
[0125] 2 Experimental Results
[0126] 2.1 Effects of different prescriptions on body weight and survival rate (Table 4)
[0127] In terms of relative weight gain rate, the relative weight gain rates of different groups of rhein: rhein: auxiliary materials were 92.2%, 84.7%, 79.5%, 68.2%, 65.2%, 83.9% and 75.7% respectively. After statistical analysis, the rhein: rhein: auxiliary materials 5:1:4 group and tylosin group were significantly higher than the infection control group ( P <0.05).
[0128] Table 4 Body weight changes and survival rate
[0129] Note: Evaluation weight gain = weight after the test - weight before the test; Relative weight gain rate = average weight gain of the test group / average weight gain of the blank control group × 100%.
[0130] 2.2 Protection results of different formulas against air sacculitis in chickens
[0131] The results are shown in Table 5. The reduction rates of air sac injury in different rhein and rhein formulations were 88.1%, 77.5%, 72.1%, 65.5%, 44.3% and 60.2%, respectively. Compared with the tylosin group, the 5:4:1 group, 4:2:4 group and 3:3:4 group showed significant differences ( P <0.05).
[0132] Table 5 Effects of different prescriptions on lesions and immune organ indexes
[0133] Note: Air sac injury score = chest air sac + abdominal air sac / number of chickens autopsied; Air sac loss reduction rate = infection control group - experimental group air sac injury volume / infection control group air sac injury score × 100%
[0134] 3 Conclusion
[0135] Therefore, from the above two aspects of relative weight gain rate and air sac injury lesion reduction rate, it can be seen that the formula of emodin: rhein: auxiliary materials 5:1:4 is better than the tylosin control group and has a better anti-Mycoplasma gallisepticum efficacy. Therefore, the drug determines that the ratio of emodin to rhein and auxiliary materials is 5:1:4.
[0136] Experimental Example 3 In vitro inhibition test of rhein and rhein complex on Mycobacterium tuberculosis
[0137] 1. Materials and Methods
[0138] 1.1 Test strains
[0139] Mycobacterium tuberculosis H37Rv (pansensitive), Mycobacterium tuberculosis AST-T2 (MDR), Mycobacterium tuberculosis AST-T3 (pansensitive), Mycobacterium tuberculosis AST-T4 (MDR), Mycobacterium tuberculosis AST-T5 (XDR), Mycobacterium tuberculosis AST-T6 (pansensitive) are maintained by the Institute of Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention.
[0140] 1.2 Test reagents
[0141] MGIT Mycobacterium Growth Indicator Culture Tube (BD Company, USA): contains 7 mL of modified Middlebrook 7H9 culture broth, fluorescent indicator, and 10% CO2.
[0142] MGIT nutritional additive OADC (BD Company, USA): mainly contains five nutrients: oleic acid, bovine serum albumin, dextran, catalyst and various vinyl stearic acids.
[0143] Color developing solution: Mix Alarmar blue color developing agent and autoclaved 5% Tween-80 solution in a volume ratio of 2:5 and use it immediately.
[0144] Physiological saline: Weigh 9 g NaCl and add it to 1000 mL pure water, mix well to make it completely dissolved, sterilize with high pressure steam and store at room temperature for later use.
[0145] Rifampicin solution: Dissolve in DMSO to 10 mg / mL, filter through a 0.22 nm filter membrane, and store at -20°C.
[0146] Rhein-rhein complex and rhein were both dissolved in DMSO at a concentration of 50 mg / mL.
[0147] 1.3 Test methods
[0148] (1) Use an inoculation loop to scrape the culture of Mycobacterium tuberculosis in the logarithmic growth phase (about 2 weeks) from the Roche medium, add it to an ultrasonic dispersion tube containing 2.5-3.5 mL of normal saline, grind the bacteria for 30 seconds, and let it stand for 15 minutes. Then adjust the turbidity to 0.5 MCF with normal saline.
[0149] (2) Dilute the 0.5 MCF bacterial solution 5 times for later use.
[0150] (3) Take 100 μL of the diluted bacterial solution in step 2 and add it to 9.9 mL of normal saline to dilute it 100 times.
[0151] (4) Add 0.8 mL of MGIT nutrient supplement and 0.5 mL of bacterial solution to each MGIT culture tube, add the bacterial solution from step 2 to the drug addition tube, and add the bacterial solution from step 3 to the growth control tube.
[0152] (5) 10 mg / mL rifampicin was diluted to 390.625 μg / mL with DMSO. Rifampicin-rhein complex and rhein were not diluted. 5.3, 10.6, 21.2, 12.5, and 85 μL of rifampicin-rhein complex and rhein were added to the tubes, respectively, to make the concentrations of 32, 64, 128, 256, and 512 μg / mL. Two parallel experiments were set up for each drug concentration.
[0153] (6) Place the inoculated culture tube into the 960 system for on-machine testing, and export the test results after a certain period of culture. The drug sensitivity determination criteria are as follows: When the GU value of the growth control tube without drug addition is greater than 400, if the GU value of the drug-containing tube is ≥100, it is determined to be drug-resistant (resistant, R); if the GU value of the drug-containing tube is less than 100, continue to culture for 7 days. If the GU value is still less than 100, it is determined to be sensitive (susceptible, S); if the GU value is ≥100, it is determined to be intermediate (intermediate, I).
[0154] 2. Test results
[0155] The results are shown in Tables 6 and 7. The two parallel controls of MGIT 960 drug sensitivity had good repeatability. Among all drug sensitivity tubes, only three pairs of inconsistencies were observed, among which 32 μg / mL of rhein-emodin complex and 256 μg / mL of rhein in AST-T4 and AST-T5, respectively, may be in the transition concentration from R to I or from I to S, which is more reasonable.
[0156] Table 6 Drug sensitivity of six strains of Mycobacterium tuberculosis to rhein-rhein complex and rhein concentration
[0157] Table 7 MIC values of rhein-rhein complex and rhein in six strains of Mycobacterium tuberculosis
[0158] Rhein-rhein complex and rhein inhibit Mycobacterium tuberculosis in vitro Figure 6 .
[0159] Conclusion: The in vitro drug sensitivity MIC values of rhein-rhein complex against 6 strains of Mycobacterium tuberculosis were 64-256 μg / mL, which was better than rhein; the MIC of rhein against 6 strains of Mycobacterium tuberculosis was 512 μg / mL, which had a certain effect. This showed that the rhein-rhein complex was better than rhein in inhibiting Mycobacterium tuberculosis.
[0160] Experimental Example 4: Experimental study on the treatment of bovine tuberculosis and brucellosis by using a Chinese medicinal composition of rhein and rhein
[0161] 1. Materials and Methods
[0162] 1.1 Experimental animals
[0163] Positive cattle: A positive cattle herd from a cattle farm in Miyun, Beijing, screened by tuberculosis and brucellosis diagnostic kits, with a number of 30 heads, no more than 2 parities, and young cows were selected to ensure sensitivity to drugs.
[0164] 1.2 Test Drugs The compound rhein and rhein Chinese medicine composition prepared in Example 3.
[0165] 1.3 Diagnostic criteria for tuberculosis and brucellosis positive cattle
[0166] Tuberculosis-positive cattle: (1) Cattle with strong positive results in whole blood interferon-γ test, or cattle with strong positive results in clinical skin test; (2) Cattle with emaciation, diarrhea, and low milk production.
[0167] Brucellosis-positive cattle: (1) Cows that have not been vaccinated with attenuated brucellosis vaccine clinically, and have positive test tube agglutination or ELISA test; (2) Cows that have been vaccinated with brucellosis vaccine clinically once and are more than 8 months old, and have positive test tube agglutination or ELISA test. (3) Cows have joint disorders and unstable standing, and low milk production.
[0168] 1.4 Grouping
[0169] There were high, medium and low dose groups of emodin and rhein, 6% rifampicin injection (Shenyang Shuangding Pharmaceutical Co., Ltd.) and blank control group, with 6 tuberculosis and brucellosis positive cattle in each group.
[0170] 1.5 Dosage and treatment (Table 8)
[0171] Rhein-rhein high-dose group: 10 mL / head; Rhein-rhein medium-dose group: 5 mL / head; Rhein-rhein low-dose group: 3 mL / head; 6% rifampicin solution: 10 mL / head; Blank control group: tuberculosis and brucellosis positive cattle, injected with 10 mL of normal saline per head.
[0172] Administration: intramuscular injection.
[0173] 1.6 Dosage regimen: Inject once every 7 days, no more than 3 times per month.
[0174] Table 8 Grouping and treatment of treatment trials
[0175] 2. Test indicators
[0176] 2.1 Overall observation indicators: mental state and changes in milk production.
[0177] Increase in milk production: The total daily milk production of each group of sick cows before and after treatment (the sum of milk production in the morning, afternoon and evening) was manually counted. The change in average daily milk production = (total daily milk production after treatment - total daily milk production before treatment) / number of sick cows. The increase in average daily milk production = change in average daily milk production of the treatment group - change in average daily milk production of the untreated group.
[0178] 2.2 Observation of treatment effect: Positive to negative (cured): The gamma-interferon release test of the whole blood sample after 30 days was negative; the Brucella serum competitive ELISA antibody detection kit was negative.
[0179] Ineffective: After 30 days, the whole blood sample was tested and the brucellosis serum was positive, and the tuberculosis interferon-γ test was positive.
[0180] 3. Test results
[0181] 3.1 Changes in milk production
[0182] As shown in Table 9, compared with the blank control group, the average daily milk production of the three groups of high, medium and low doses of rhein-rhein increased by 6.30, 6.99 and 5.04 L / head, respectively, while the average daily milk production of the rifampicin group increased by 6.24 L / head. Compared with the rifampicin control group, the average daily milk production of the high and medium doses of rhein-rhein groups increased by 0.06 and 0.74 L / head. This suggests that the Chinese medicine composition of rhein and rhein can improve growth performance and promote milk production.
[0183] Table 9 Effect of the Chinese medicinal composition of rhein and rhein on milk production of tuberculosis and brucellosis positive cows
[0184] 3.2 Changes in the negative conversion rate of brucellosis and tuberculosis
[0185] As shown in Table 10, from the perspective of tuberculosis negative conversion rate, the negative conversion rates of the high, medium and low dose groups of emodin-rhein were 16.7%, 50.0% and 16.7%, respectively, among which the negative conversion rate of the medium dose group of emodin-rhein was higher than that of the positive control group of rifampicin. From the perspective of brucellosis negative conversion rate, the negative conversion rates of the high, medium and low dose groups of emodin-rhein were 16.7%, 33.3% and 16.7%, respectively, which were higher than the positive control group of rifampicin, and the medium dose group was close to rifampicin. The above results show that the effect of the Chinese medicine composition of emodin and rhein in treating tuberculosis and brucellosis in dairy cows is better than that of rifampicin.
[0186] Table 10 Effect of Chinese herbal medicine combination on negative conversion rate of tuberculosis and brucellosis positive cattle
[0187] Comprehensive analysis shows that the Chinese herbal combination of rhein and rhein acid can promote the conversion of tuberculosis and brucellosis in dairy cows to negative, and significantly improve production performance. Moreover, compared with antibiotics for the treatment of bovine tuberculosis and brucellosis, the Chinese herbal combination of rhein and rhein acid has the advantages of short treatment cycle and low cost, and the therapeutic effect is better than rifampicin.
[0188] Conclusion: The Chinese medicinal composition of rhein and rhein, injected at 5-10 mg / kg body weight, 3 times / month, can effectively treat tuberculosis and brucellosis in dairy cows, and significantly increase milk production and improve growth performance.
[0189] Experimental Example 4 Comparison of the effects of rhein and rhein in the treatment of tuberculous mastitis Figure 5 .
[0190] Experimental Example 5: Expanded Experiment on the Prevention and Treatment of Brucella Disease in Dairy Cows Using the Chinese Medicine Composition of Rhein and Rhein
[0191] 1. Materials and methods
[0192] 1.1 Experimental animals
[0193] Positive cattle: 108 positive cattle screened by the brucellosis diagnostic kit, with a gestational age of no more than 2. Young cows were selected to ensure sensitivity to the drug.
[0194] 1.2 Experimental groups and treatments are shown in Table 11.
[0195] Table 11 Experimental groups and treatments
[0196] 1.3 Diagnostic criteria for brucellosis-positive cattle
[0197] Brucellosis-positive cattle: (1) positive in clinical tube agglutination or ELISA test; (2) clinically vaccinated against brucellosis once and more than 8 months old, with positive in tube agglutination or ELISA test. (3) The cattle have joint disorders and unstable standing, and low milk production.
[0198] 2. Test indicators
[0199] 2.1 Observation indicators
[0200] Changes in milk production: The total daily milk production of sick cows in each group before and after treatment (the sum of milk production in the morning, afternoon and evening) was manually counted. The change in average daily milk production = (total daily milk production after treatment - total daily milk production before treatment) / number of sick cows. The increase in average daily milk production = change in average daily milk production of the treatment group - change in average daily milk production of the untreated group.
[0201] 2.2 Observation of treatment effect: Positive to negative (cured): Brucella competitive ELISA kit antibody test and conventional PCR antigen test in serum samples were negative after 30 days.
[0202] Ineffective: Whole blood samples were tested 30 days later and the result was positive for brucellosis serotype, but there was no increase in milk production.
[0203] 3. Test results
[0204] 3.1 Effect of rhein-rhein Chinese medicine combination on milk production of tuberculosis and brucellosis positive dairy cows
[0205] From the changes in daily average milk production in Table 12, compared with the blank control group, the daily average milk production of the emodin-rhein group increased by 1.57 L / head, which was much higher than the 0.3 L / head of the rifampicin group, and the blank control group showed a negative growth phenomenon. This shows that emodin-rhein can improve the growth performance of tuberculosis and brucellosis positive dairy cows.
[0206] Table 12 Effect of the Chinese medicinal composition of rhein and rhein on milk production of brucellosis positive dairy cows
[0207] 3.2 Effect of the Chinese medicinal composition of rhein and rhein on the negative conversion rate of brucellosis-positive cattle
[0208] Table 13 shows that the negative conversion rate of Mycobacterium tuberculosis in the rhein-rhein group reached 100%, while that in the rifampicin control group was 38.7%, which was significantly higher than that in the control group. On the contrary, the negative conversion rate of brucellosis in the rhein-rhein group was 29.03%, while that in the rifampicin control group was 19.4%, with no significant difference.
[0209] Table 13 Effect of the Chinese medicinal composition of rhein and rhein on the negative conversion rate of brucellosis positive cattle
[0210] Conclusion: Continuous injection of rhein-emodin injection liquid for 4 times with an interval of 7 days can significantly reduce the positive rate of tuberculosis and brucellosis and increase milk production, thus providing scientific support for the purification of tuberculosis and brucellosis.
[0211] The general description and specific embodiments have been described in detail for the present invention, but it is obvious to those skilled in the art that some modifications or improvements can be made on the basis of the present invention. Therefore, these modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A composition of rhein and rhein, characterized in that: The mass ratio of the active ingredients emodin and rhein is (10-50):(5-10), preferably 5:
1.
2. The composition according to claim 1, characterized in that The composition also includes a pharmaceutically acceptable adjuvant or excipient; The mass percentages of rhein and rhein in the composition are 10-50% and 5-10% respectively, and the rest are pharmaceutical adjuvants or excipients.
3. The composition according to claim 2, characterized in that The composition contains 50% of rhein, 10% of rhein and 40% of pharmaceutical adjuvants or excipients; wherein % is the mass percentage.
4. The composition according to any one of claims 1 to 3, characterized in that The pharmaceutical excipient is selected from at least one of medium chain triglycerides, 1,2-propylene glycol, Tween-20, and Tween-80; The excipient is selected from at least one of starch, dextrin, lactose, stevioside, sucrose, glycyrrhizin, fructose syrup, sucralose, xylitol, sorbitol, glucose and sodium carboxymethyl starch.
5. Use of the composition according to any one of claims 1 to 4 in the preparation of an antibacterial agent or an antibacterial drug; The bacteria are selected from Mycobacterium tuberculosis, non-tuberculous mycobacteria, Brucella, and avian mycoplasma.
6. Use of the composition according to any one of claims 1 to 4 in the preparation of a medicament for preventing and treating intracellular bacterial infection in livestock and poultry; The intracellular bacterial infection of livestock and poultry is caused by Mycobacterium tuberculosis, non-tuberculous mycobacteria, Brucella or avian mycoplasma.
7. The use according to claim 5 or 6, characterized in that: The avian mycoplasma includes Mycoplasma gallisepticum and Mycoplasma synoviae.
8. The use according to any one of claims 5 to 7, characterized in that: The medicine is in the form of granules, powders, oral liquids, infusions, tablets or injections.
Citation Information
Patent Citations
Medicine composition containing parietic acid and pharmaceutical purpose of medicine composition
CN105012283A
Emodin methyl ether microemulsion and application thereof
CN114831937A
Application of aloe-emodin or composition of aloe-emodin and tylosin in inhibition of mycoplasma gallisepticum and mycoplasma synoviae
CN116036059A
Application of quinone compound in prevention and treatment of dairy cow mastitis pathogenic bacteria
CN118203563A
Production of rhein and rhein derivatives
US5652265A
